Introduction {#s1}
============

Macroautophagy (hereafter referred to as autophagy) delivers cytoplasmic materials such as protein aggregates and organelles to lysosomes for degradation. The resulting catabolites are reutilized to maintain cellular homeostasis under both stress and physiological conditions ([@bib29]; [@bib23]). During autophagy, bulk cytosol may be randomly sequestered into double-membrane autophagosomes, which eventually fuse with lysosomes where cargos are degraded ([@bib41]; [@bib31]). On the other hand, specific substrates can be recognized and removed through selective autophagy ([@bib4]). In both cases, multiple protein complexes act coordinately to control the initiation, formation and maturation of autophagosomes as well as their fusion with lysosomes ([@bib31]; [@bib42]).

A variety of cellular components including organelles are found to be substrates of autophagy. Ribosomes were among the first few cargos detected in the interior of autophagosomes by electron microscopy and have served as a marker of bulk cytoplasm degradation ([@bib2]; [@bib6]). In addition to non-selective autophagy, prolonged nitrogen starvation in yeast leads to ribophagy, during which mature ribosomes are selectively targeted and removed by autophagy ([@bib20]). In ribophagy, the large and small ribosomal subunits appear to be independently targeted for degradation, which involves both ubiquitination and deubiquitination ([@bib20]; [@bib21]; [@bib32]; [@bib33]; [@bib5]). Ribosomes contain about 50% of the cellular proteins and 80% of total RNA. Both ribosomal proteins and RNAs are processed in lysosomes during autophagy-mediated degradation, which may serve as the major source of amino acids and nucleotides in nutrient deprivation conditions ([@bib14]; [@bib22]). It is therefore not surprising that autophagic degradation of ribosomes is crucial for survival of yeast cells in nutrient starvation ([@bib20]). However, it remains unclear whether mature ribosomes are degraded through autophagy under normal growth conditions and whether ribosome degradation contributes to animal physiology.

*C. elegans* embryos are wrapped in tough eggshells that are impermeable to most solutes. The development of embryos from the one-cell stage to the end of embryogenesis (558 cells) relies on degradation of maternally loaded materials, independent of external nutrients. The maternally loaded yolk proteins are degraded in lysosomes, while PGL granules and aggregates of SQST-1/p62 and SEPA-1 family proteins are removed by autophagy ([@bib24]; [@bib39]; [@bib43]; [@bib25]). The resulting catabolites are recycled from lysosomes to provide energy and essential building blocks for embryogenesis. Impairing autophagy or lysosome function leads to reduced hatching rate and retarded embryonic development ([@bib44]; [@bib38]; [@bib25]; [@bib37]). It is unclear whether ribosomes, which contain abundant proteins and RNAs, may be used as a nutrient source for development.

In this study, we identified RNST-2, the *C. elegans* T2 family endoribonuclease, from a genetic screen for lysosome-defective mutants. We found that loss of RNST-2 causes accumulation of rRNA and ribosomal proteins in lysosomes in an autophagy-dependent manner. *rnst-2(lf)* worms are defective in embryonic and larval development and have shortened lifespans. Our data indicate that autophagy-dependent degradation of ribosomal RNA is important for maintaining nucleotide homeostasis, which is essential for development.

Results {#s2}
=======

*qx245* mutants contain abnormal lysosomes {#s2-1}
------------------------------------------

From a forward genetic screen for mutants with lysosomal defects, we isolated *qx245*, which contained abnormally enlarged lysosomes. In wild type, lysosomes labeled by the lysosomal membrane protein LAAT-1::GFP and the lysosomal DNase II NUC-1::CHERRY appeared as small puncta and thin tubules, with an average volume of 0.77 μm^3^ in 4-fold embryos and L1 larvae ([Figure 1A,D,G,J,M](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1A,D,G,J,M,P](#fig1s1){ref-type="fig"}) ([@bib10]; [@bib25]). In *qx245* mutants, however, enlarged lysosomes were observed at embryonic, larval and adult stages in multiple cell types including hypodermal cells, muscle cells and sheath cells ([Figure 1B,E,H,K](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1B,E,H,J,K,M,N](#fig1s1){ref-type="fig"}). The average volume of lysosomes reached 2.85 μm^3^ in *qx245* embryos and L1 larvae, and 5.67 μm^3^ in adult hypodermis, which is 3.7 and 2.5 times bigger than in wild type, respectively ([Figure 1M](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1P](#fig1s1){ref-type="fig"}). The enlargement of lysosomes in *qx245* was observed from late embryonic to early larval stages, and at the adulthood ([Figure 1---figure supplement 1Q](#fig1s1){ref-type="fig"}). We found that the enlarged lysosomes in *qx245* mutants were stained by Lysotracker Red to a similar extent as in wild type, suggesting that lysosome acidification is not affected ([Figure 1J--K", N](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1R](#fig1s1){ref-type="fig"}).

![*rnst-2* mutants accumulate enlarged lysosomes.\
(**A--I**) Confocal fluorescence images of embryos at the 4-fold stage (4F, **A--C**), larvae 1 (L1, **D--F**) and adult hypodermis (**G--I**) in wild-type (WT, **A, D, G**), *rnst-2(qx245)* (**B, E, H**) and *rnst-2(bp555)* (**C, F, I**) expressing LAAT-1::GFP. (**J--L"**) Confocal fluorescence images of the hypodermis in wild-type (**J--J″**), *rnst-2 (qx245)* (**K--K″**) and *rnst-2(bp555)* (**L--L″**) adults expressing LAAT-1::GFP and stained by Lysotracker red. In (**A--L''**), white arrowheads and arrows indicate globular and tubular lysosomes, respectively, and blue arrowheads indicate enlarged globular lysosomes. Scale bars: 5 µm. (**M**) Quantification of the average volume of lysosomes labeled by LAAT-1::GFP in 4-fold-stage embryos (4F), L1 larvae (**L1**) and adult hypodermis (day 3 of adulthood). (**N**) The percentage of LAAT-::GFP-positive lysosomes that were stained by lysotracker red was quantified in adult hypodermis. In (**M, N**), at least 10 worms were scored in each strain at each stage. Data are shown as mean ± SD. Two-way ANOVA with the Bonferroni *post hoc* test (**M**) or one-way ANOVA with Tukey's *post hoc* test (**N**) was performed to compare mutant datasets with wild type. \*\*\*p\<0.001, other points had p\>0.05.\
10.7554/eLife.36588.005Figure 1---source data 1.[Figure 1](#fig1){ref-type="fig"} numerical data.\
10.7554/eLife.36588.006Figure 1---source data 2.[Figure 1---figure supplement 1](#fig1s1){ref-type="fig"} numerical data.](elife-36588-fig1){#fig1}

*qx245* affects RNST-2, a widely expressed lysosomal T2 endoribonuclease {#s2-2}
------------------------------------------------------------------------

The *qx245* mutation affects the gene *rnst-2*, which encodes a T2 family endoribonuclease (RNase T2) ([Figure 1---figure supplement 2A and L](#fig1s2){ref-type="fig"}). RNase T2 family enzymes catalyze cleavage of single-stranded RNA at all four bases with an optimal pH of 4--5 ([@bib27]). These enzymes perform diverse functions in a wide variety of organisms by processing extracellular and intracellular RNAs ([@bib27]). We found that *qx245* carried a G-to-A mutation in *rnst-2* that resulted in the replacement of Gly 119 by Glu ([Figure 1---figure supplement 2L](#fig1s2){ref-type="fig"}). *bp555*, an independently isolated *rnst-2* mutant allele, caused a premature stop codon after Pro 55. The G119E mutation in *qx245* affected the second catalytic active site (CAS II), whereas both CAS I and II were lost in *bp555*, suggesting that *qx245* and *bp555* are strong loss-of-function or null mutations of *rnst-2* ([Figure 1---figure supplement 2L](#fig1s2){ref-type="fig"}). Consistent with this, enlarged lysosomes were observed in *bp555*, like in *qx245* ([Figure 1C,F,I,L,M](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1C,F,I,L,O,P](#fig1s1){ref-type="fig"}). *C. elegans* RNST-2 shares 47% sequence similarity and 29% sequence identity with human RNASET2 ([Figure 1---figure supplement 2L](#fig1s2){ref-type="fig"}). Expression of RNST-2 or human RNASET2 controlled by the *rnst-2* promoter efficiently rescued the enlarged lysosome phenotype in *qx245* mutants, suggesting that RNASET2 can substitute for worm RNST-2 in maintaining lysosome morphology ([Figure 1---figure supplement 2C,E--G,I](#fig1s2){ref-type="fig"}).

We generated a RNST-2::CHERRY reporter driven by the *rnst-2* promoter, which fully rescued the lysosome phenotypes in *qx245* and *bp555* mutants ([Figure 1---figure supplement 2C,F,G,J,K](#fig1s2){ref-type="fig"}). RNST-2::CHERRY was widely expressed from embryonic stages throughout larval and adult stages in various tissues, including pharynx, hypodermis, muscle, sheath cells, intestine cells, vulva and tail region ([Figure 2A--H'](#fig2){ref-type="fig"}). RNST-2::CHERRY stained both puncta and tubular structures that were labeled by the lysosomal membrane proteins LAAT-1::GFP and SCAV-3::GFP, indicating that RNST-2 localizes to lysosomes ([Figure 2I--J"](#fig2){ref-type="fig"}).

![RNST-2 is widely expressed and localizes to lysosomes.\
(**A--H′**) DIC and confocal fluorescence images of wild type expressing RNST-2::CHERRY driven by the *rnst-2* promoter. RNST-2::CHERRY is expressed from early embryos (**A, A'**) to the adult stage in various cell types including hypodermis (**B, B'**), intestine (**C, C'**), sheath cell (**D, D'**), pharynx (**E, E'**), tail (**F, F'**), vulva (**G, G'**) and muscle cell (**H, H'**). (I--J″) Confocal fluorescence images of the hypodermis in wild type co-expressing RNST-2::CHERRY and LAAT-1::GFP (I--I″) or SCAV-3::GFP (J--J″). RNST-2 colocalizes with LAAT-1 and SCAV-3 to both globular (arrowheads) and tubular (arrows) lysosomes. Scale bars: 5 µm.](elife-36588-fig2){#fig2}

*rnst-2(lf)* lysosomes accumulate rRNA and ribosomal proteins in an autophagy-dependent manner {#s2-3}
----------------------------------------------------------------------------------------------

To determine whether RNST-2 functions as a ribonuclease in lysosomes, we performed rescue experiments. Expression of wild-type RNST-2, but not RNST-2(H118A), which carries a mutation in the histidine residue (H118) essential for the catalytic activity of endoribonuclease T2 ([@bib18]), rescued the enlarged lysosome phenotype of *rnst-2(qx245)* mutants, indicating that catalytic activity of RNST-2 is important for its function in lysosomes ([Figure 1---figure supplement 2C,D,G,H](#fig1s2){ref-type="fig"}). We purified lysosomes from wild type and *rnst-2* worms and extracted RNA from lysosomes ([Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}) ([@bib25]). We found that *rnst-2(qx245)* and *rnst-2(bp555)* lysosomes accumulated high levels of RNA, especially 26S and 18S rRNA ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). The total RNA level in *rnst-2* lysosomes was more than five times higher than in wild type ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). Moreover, lysosomal accumulation of ribosomal proteins from the large and small subunits was observed in *rnst-2(qx245)* and *rnst-2(bp555)* but not wild-type worms ([Figure 3B](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). The lysosomal accumulation of RNA and ribosomal proteins in *rnst-2(qx245)* mutants was fully suppressed by expression of RNST-2 ([Figure 3A and B](#fig3){ref-type="fig"}). These data indicate that loss of RNST-2 disrupts ribosomal RNA degradation in lysosomes. The defective degradation of rRNA in *rnst-2* lysosomes may impair further digestion of ribosomes, causing accumulation of ribosomal proteins in lysosomes.

![Loss of RNST-2 causes accumulation of rRNA and ribosomal proteins in lysosomes in an autophagy-dependent manner.\
(**A, C**) RNA purified from lysosomes in the indicated strains was examined by agarose gel electrophoresis. Full processing of the lysosomal cathepsin CPL-1 (dc-CPL-1) was used to normalize the amount of lysosomes in each strain. The total extracted RNA was quantified and normalized to 1-fold in wild type (A, C, right panel). Abundant 26S and 18S rRNA was observed in lysosomes of *rnst-2(qx245)* mutants. At least three independent experiments were performed and data are shown as mean ± SD. (**B, D**) Accumulation of ribosomal proteins (large subunit: RPL-5, RPL-25.2; small subunit: RPS-3 and RPS-0) and LGG-1 in lysosomes was examined by western blot analysis in the indicated strains. Full processing of the lysosomal cathepsin CPL-1 (dc-CPL-1) was used to normalize the amount of lysosomes in each strain. (**E--H**) 3D reconstitution of the fluorescence images in 10--15 *z*-series (0.5 µm/section) in L1 larvae of the indicated strains expressing LAAT-1::GFP. Enlarged lysosomes (arrowheads) were observed in *rnst-2(qx245)*. (**I**) Quantification of the average volume of lysosomes in the strains shown in (**E--H**). At least 10 worms were scored in each strain and data are shown as mean ± SD. In (**A, C, I**), one-way ANOVA with Tukey's *post hoc* test was performed to compare all other datasets with wild type or datasets that are linked by lines (**I**). \*\*\*p\<0.0001, N.S.: no significance.\
10.7554/eLife.36588.011Figure 3---source data 1.[Figure 3](#fig3){ref-type="fig"} numerical data.\
10.7554/eLife.36588.012Figure 3---source data 2.[Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} numerical data.\
10.7554/eLife.36588.013Figure 3---source data 3.[Figure 3---figure supplement 2](#fig3s2){ref-type="fig"} numerical data.](elife-36588-fig3){#fig3}

We next investigated whether autophagy is responsible for delivering ribosomal RNA to lysosomes. ATG-2/ATG2 and EPG-6/WIPI4 regulate autophagosome formation and loss of their functions disrupt progression from phagophores to complete autophagosomes ([@bib39]; [@bib26]). We found that mutation of *atg-2* or *epg-6* completely suppressed lysosomal accumulation of rRNA and ribosomal proteins in *rnst-2(qx245)* mutants ([Figure 3C,D](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1E,F](#fig3s1){ref-type="fig"}). Moreover, lysosome volume, which was greatly increased in *rnst-2(qx245)*, was reduced significantly in *rnst-2;atg-2* double mutants ([Figure 3E--I](#fig3){ref-type="fig"}). Loss of EPG-6 or LGG-1, the *C. elegans* homolog of Atg8/LC3, also led to greatly reduced lysosome volume in *rnst-2* ([Figure 3---figure supplement 1G--M](#fig3s1){ref-type="fig"}). Altogether, these data suggest that rRNA and ribosomal proteins are delivered to lysosomes through autophagy and defects in their degradation lead to enlargement of lysosomes in *rnst-2* mutants.

Loss of RNST-2 does not affect endocytic and phagocytic cargo degradation but partially impairs autophagy {#s2-4}
---------------------------------------------------------------------------------------------------------

*rnst-2* mutants accumulate ribosomal RNA and proteins that are delivered to lysosomes by autophagy. We next examined whether loss of RNST-2 also affects degradation of endocytic and phagocytic cargos. Cell surface protein CAV-1 and yolk lipoprotein VIT-2 are delivered to lysosomes through the endocytic pathway and are degraded shortly after fertilization and during embryogenesis, respectively ([@bib35]; [@bib9]). In *rnst-2(qx245)* embryos, both VIT-2::GFP and CAV-1::GFP were properly degraded as in wild type ([Figure 3---figure supplement 2A--H'](#fig3s2){ref-type="fig"}). Moreover, *rnst-2(qx245)* mutants contained similar numbers of embryonic and germ cell corpses as in wild type, suggesting that phagocytosis and degradation of apoptotic cells is unaffected ([Figure 3---figure supplement 2I,J](#fig3s2){ref-type="fig"}). These data suggest that lysosomal degradation of endocytic and phagocytic cargos is not affected in *rnst-2(lf)* mutants. *rnst-2(lf)* lysosomes contained high levels of LGG-1, which associates with autophagosomes and their precursors ([Figure 3B](#fig3){ref-type="fig"}). This lysosomal accumulation of LGG-1 is consistent with defects in degrading autophagic cargos ([@bib39]). We next examined whether the autophagy process is affected in *rnst-2* mutants. The PGL granule component PGL-3 is removed in soma by selective autophagy during embryogenesis, which requires the bridging molecule SEPA-1 ([@bib43]). PGL-3 and SEPA-1 puncta persisted in autophagy-defective mutants such as *atg-2* ([Figure 4---figure supplement 1C,C', F,F'](#fig4s1){ref-type="fig"}) ([@bib43]), but were removed in both wild-type and *rnst-2* embryos, suggesting that autophagic clearance of PGL granules is unaffected in *rnst-2* mutants ([Figure 4---figure supplement 1A--B', D--E'](#fig4s1){ref-type="fig"}). SQST-1 is the *C. elegans* p62 homolog that associates with various protein aggregates and is removed by autophagy ([@bib39]). SQST-1 puncta were cleared in wild-type embryos, present in late-staged *rnst-2* mutant embryos, and persisted at both early and late stages in *atg-2* embryos ([Figure 4A--I'](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1G--I'](#fig4s1){ref-type="fig"}). Similarly, LGG-1, which associates with autophagic structures and is a substrate of autophagy, was present in *atg-2* embryos at both early and late stages, but accumulated only in late-staged embryos in *rnst-2* mutants ([Figure 4J--R'](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1J--L'](#fig4s1){ref-type="fig"}). In addition, GFP::ATG-18, the PtdIns3P-binding protein that associates with early autophagic structures ([@bib26]), was diffuse in the cytoplasm in both wild type and *rnst-2(lf)*, suggesting that autophagosome formation is not blocked ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). Altogether, these data suggest that the autophagy process is partially impaired or delayed in *rnst-2(lf)*, causing accumulation of SQST-1 and LGG-1 in late-staged embryos. Consistent with this, *rnst-2* mutants accumulated both LGG-1-I and LGG-1-II (lipid-conjugated form of LGG-1) at embryonic and adult stages ([Figure 4S and T](#fig4){ref-type="fig"}). Moreover, loss of *rnst-2* significantly shortened the lifespan of the L1 larvae in the absence of food ([Figure 4U](#fig4){ref-type="fig"}), a process that requires autophagy activity ([@bib17]).

*rnst-2* mutants are defective in embryogenesis and larval development, and are short-lived {#s2-5}
-------------------------------------------------------------------------------------------

*rnst-2* mutants are viable but grow slowly. Both *rnst-2(qx245)* and *rnst-2(bp555)* were retarded in embryogenesis and exhibited 20--30% embryonic lethality ([Figure 5A and B](#fig5){ref-type="fig"}). Moreover, approximately 50% of *rnst-2(qx245)* and *rnst-2(bp555)* embryos that hatched were arrested during larval development, and this arrest was rescued by expression of RNST-2 ([Figure 5C](#fig5){ref-type="fig"}). These data indicate that loss of *rnst-2* severely affects embryonic and larval development. In addition to affecting development, *rnst-2* mutants are short-lived compared with wild type ([Figure 5D and E](#fig5){ref-type="fig"}). To further investigate the effect of *rnst-2(lf)* on lifespan, we examined whether loss of *rnst-2* affects the lifespan of long-lived mutants. Reducing insulin signaling extends the lifespan in *C. elegans* ([@bib30]). Worms that carry a loss-of-function mutation in the insulin receptor DAF-2 live twice as long as wild-type worms ([Figure 5D and E](#fig5){ref-type="fig"}) ([@bib19]). We found that loss of *rnst-2* significantly reduced the lifespan of *daf-2(lf)* worms to the wild-type level ([Figure 5D and E](#fig5){ref-type="fig"}). Moreover, loss of *rnst-2* also reduced the lifespan of *glp-1(e2144)*, which affects germline stem cells and thus extends lifespan ([Figure 5F and G](#fig5){ref-type="fig"}) ([@bib1]). These data suggest that RNST-2 function is important for maintaining normal lifespan and for the lifespan extension in *daf-2* and *glp-1*.

![Autophagy is partially impaired in *rnst-2* mutants.\
(**A--R'**) Confocal fluorescence images of embryos in wild type (WT), *rnst-2(qx245)* and *atg-2(bp576)* at 200 cell (**A--C', J--L"**), comma (**D--F', M--O'**) and 4-fold (**G--I', P--R'**) stages stained by anti-SQST-1 (**A--I'**) or anti-LGG-1 antibodies (**J--R'**). DAPI staining shows nuclei in each embryo. Scale bars: 5 µm. (**S, T**) Western blot analysis of LGG-1-I and LGG-1-II (lipid-conjugated form) in wild-type, *rnst-2(qx245)*, *rnst-2(bp555)* and *atg-2(bp576)* at the embryonic (**S**) and adult stages (day 3 of adulthood) (**T**). (**U**) The survival of L1 larvae in the absence of food was quantified in the indicated strains. At least 200 animals were scored at each time point in each strain. three independent experiments were performed and the mean lifespan of L1 larvae in the absence of food was quantified (right panel). The data are shown as mean ± SD. One-way ANOVA with Tukey's *post hoc* test was performed to compare mutant datasets with wild type. \*\*\*p\<0.0001, N.S., no significance.\
10.7554/eLife.36588.017Figure 4---source data 1.[Figure 4](#fig4){ref-type="fig"} numerical data.](elife-36588-fig4){#fig4}

![*rnst-2* mutants are defective in embryogenesis and larval development, and are short-lived.\
(**A--C**) Embryonic and larval development was examined in wild type, *rnst-2(qx245)* and *rnst-2(bp555)*. At least 150 embryos and 100 larvae were examined in each strain and at least three independent experiments were performed. (**D--G**) Lifespan analyses were performed in the indicated strains. More than 100 worms were examined in each strain and three independent experiments were performed. The mean lifespan in the indicated strains was quantified and is shown in (**E, G**). Data are shown as mean ± SD. One-way ANOVA with Tukey's *post hoc* test was performed to compare datasets with wild type or datasets that are linked by lines. \*p\<0.05, \*\*p\<0.001, \*\*\*p\<0.0001.\
10.7554/eLife.36588.019Figure 5---source data 1.[Figure 5](#fig5){ref-type="fig"} numerical data.](elife-36588-fig5){#fig5}

Simultaneous loss of *rnst-2* and de novo synthesis of pyrimidines leads to synthetic embryonic lethality {#s2-6}
---------------------------------------------------------------------------------------------------------

RNST-2 is an endoribonuclease that degrades RNA in lysosomes. We suspected that defective RNA degradation in *rnst-2(lf)* mutants affects generation and recycling of RNA catabolites, which are important for animal development. Pyrimidine and purine nucleotides are essential components of RNA. They are produced through both de novo and salvage pathways and are building blocks for the synthesis of RNA, DNA, phospholipids and nucleotide sugars ([@bib15]). As purine metabolic pathways are not well understood in *C. elegans* and the key enzyme involved in purine biosynthesis is not clearly identified, we focused on the pyrimidine pathway. PYR-1/CAD and UMPS-1/UMPS are two key enzymes required for the de novo synthesis of UMP, the precursor for other pyrimidine nucleotides ([@bib28]; [@bib8]; [@bib15]). *pyr-1(cu8)* and *umps-1(mn160)* single mutants exhibited 50% and 25% embryonic lethality, respectively, indicating that pyrimidine biosynthesis is important for embryogenesis ([Figure 6A and B](#fig6){ref-type="fig"}). We found that loss of *rnst-2* and *pyr-1* or *rnst-2* and *umps-1* led to almost 100% embryonic lethality ([Figure 6A,B](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}). By contrast, loss of the lysosomal amino acid transporter LAAT-1, which blocks transport of lysine and arginine out of lysosomes, did not cause increased embryonic lethality in *pyr-1* or *umps-1* mutants ([Figure 6A and B](#fig6){ref-type="fig"}) ([@bib25]). Moreover, loss of LMP-1, the lysosomal membrane protein homologous to human LAMP1, did not affect embryonic and larval development, and had no effect on the embryonic viability in *pyr-1* or *umps-1* ([Figure 6---figure supplement 1C--E](#fig6s1){ref-type="fig"}). These data suggest that loss of RNST-2 function, but not a general defect of lysosomes, leads to the synthetic embryonic lethality in *pyr-1* or *umps-1* mutants. Similar to *rnst-2(lf)*, the *pyr-1(cu8)* mutation also caused a significantly shortened lifespan in *daf-2(lf)* worms, whereas *laat-1(qx42)* was less effective in reducing the *daf-2(lf)* lifespan ([Figure 6---figure supplement 1F--I](#fig6s1){ref-type="fig"}). These data suggest that maintenance of pyrimidine homeostasis is important for extended lifespan in *daf-2(lf)*.

![RNST-2 maintains pyrimidine availability for embryonic development.\
The percentage of viable embryos was scored in the indicated strains without (**A, B**) or with uridine (**C, D**) or cytidine supplementation (**E, F**). At least 150 embryos were examined in each strain and three independent experiments were performed. Data are shown as mean ± SD. One-way ANOVA with Tukey's *post hoc* test was performed to compare all other datasets with wild type or datasets that are linked by lines. \*p\<0.05, \*\*p\<0.001, \*\*\*p\<0.0001, N.S.: no significance.\
10.7554/eLife.36588.023Figure 6---source data 1.[Figure 6](#fig6){ref-type="fig"} numerical data.\
10.7554/eLife.36588.024Figure 6---source data 2.[Figure 6---figure supplement 1](#fig6s1){ref-type="fig"} numerical data.\
10.7554/eLife.36588.025Figure 6---source data 3.[Figure 6---figure supplement 2](#fig6s2){ref-type="fig"} numerical data.](elife-36588-fig6){#fig6}

To further test whether lysosomal degradation of rRNA by RNST-2 is important in providing pyrimidines during embryonic development, we performed pyrimidine supplement experiments. External supplement of uridine had no effect on embryogenesis in wild type, but efficiently suppressed the synthetic embryonic lethality in *pyr-1;rnst-2* double mutants ([Figure 6C](#fig6){ref-type="fig"}). The embryonic lethality in *umps-1;rnst-2* was partially relieved by uridine supplement, consistent with the idea that UMPS-1 acts in both de novo and salvage pathways to synthesize UMP ([Figure 6D](#fig6){ref-type="fig"}) ([@bib28]). We found that cytidine supplement caused reduced viability of wild-type embryos, but it partially suppressed the synthetic embryonic lethality in *pyr-1;rnst-2* and *umps-1;rnst-2* double mutants, albeit to a lesser extent than uridine supplements ([Figure 6E and F](#fig6){ref-type="fig"}). These data suggest that RNA degradation by RNST-2 in lysosomes is important in maintaining pyrimidine homeostasis during embryogenesis. We found that the autophagy-defective mutations *lgg-1(bp500)*, *atg-2(bp576)*, *atg-18(gk378)* and *atg-9(bp564)* partially affected embryogenesis and caused synthetic embryonic lethality in *pyr-1(RNAi)* and *umps-1(RNAi)* worms, consistent with the role of autophagy in delivering RNA to lysosomes ([Figure 6---figure supplement 1A,B](#fig6s1){ref-type="fig"}). Supplements of uridine or cytidine did not obviously improve the embryonic viability of *rnst-2(qx245)* single mutants or in autophagy-defective mutants ([Figure 6C--F](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1C,D](#fig6s1){ref-type="fig"}), suggesting that a general autophagy defect may contribute to the partial embryonic lethality in these worms.

Discussion {#s3}
==========

RNST-2 degrades ribosomal RNA delivered by autophagy in lysosomes {#s3-1}
-----------------------------------------------------------------

Here we identified *C. elegans* RNST-2, a T2 family endoribonuclease, as a key enzyme that degrades ribosomal RNA in lysosomes. RNST-2 localizes to lysosomes and loss of its function causes rRNA accumulation in enlarged lysosomes in an autophagy-dependent manner. Thus, RNST-2 degrades rRNA delivered by autophagy in lysosomes, which is consistent with the function of Ryn1 and RNS2, the yeast and *Arabidopsis thaliana* T2 family endoribonucleases, respectively ([@bib14]; [@bib7]). Loss of zebrafish *rnaset2* results in accumulation of undigested rRNA in lysosomes of neurons ([@bib12]), while expression of human RNASET2 in worms efficiently rescued the lysosome phenotype in *rnst-2* mutants ([Figure 1---figure supplement 2E,I](#fig1s2){ref-type="fig"}). Thus, T2 family endoribonuclease acts as the key enzyme to degrade ribosomal RNA in lysosomes in diverse species throughout evolution. The *rnst-2* lysosomes appear to accumulate intact 26S and 18S rRNA, suggesting that mature ribosomes are targeted for degradation. In addition to rRNA, *rnst-2* lysosomes also contain high levels of ribosomal proteins, suggesting that rRNA degradation may facilitate destruction and further digestion of ribosomes. Our data suggest that the autophagy process is partially impaired in *rnst-2* mutants. We suspect that gradual buildup of undigested rRNA and ribosomal proteins in lysosomes leads to impaired autophagy kinetics and thus reduction in autophagic flux. Consistent with this, dysregulation of autophagy has been commonly found in lysosomal storage disorders characterized by the accumulation of undegraded metabolites in lysosomes ([@bib36]).

Ribosomal RNA degradation through the autophagy-lysosome pathway is important in maintaining nucleotide homeostasis essential for animal development {#s3-2}
----------------------------------------------------------------------------------------------------------------------------------------------------

Bulk or selective degradation of ribosomes via the autophagy-lysosome pathway is important for cell survival under nutrient deprivation conditions, but whether it occurs under normal conditions and is important for animal physiology remains unclear. Here, we found that loss of RNST-2 function affects degradation of ribosomal RNA and proteins, and causes severe developmental defects, suggesting that ribosome degradation occurs under normal growth conditions and is important for animal development. Importantly, simultaneous loss of RNST-2 or autophagy and the de novo synthesis of pyrimidines causes complete embryonic lethality, and this synthetic lethality can be suppressed by exogenous supply of uridine or cytidine. This indicates that rRNA turnover through the autophagy-lysosome pathway plays an important role in maintaining nucleotide homeostasis during development. We have attempted to measure the nucleoside levels by LC/MS in *rnst-2;pyr-1(RNAi)* embryos, and observed a reduction in cytidine but not guanosine (data not shown). Given that the nucleoside levels were measured in embryonic lysates prepared from unhealthy embryos with an intact purine synthesis pathway but containing heterogeneous tissues and both intracellular and extracellular nucleosides, the results may not reflect the situation in key tissues that cause the phenotype.

The nucleosides or nucleobases derived from lysosomal rRNA turnover may be re-utilized through the pyrimidine salvage pathway to provide precursors to multiple metabolic pathways essential for development ([@bib14]; [@bib15]). In *rnst-2* embryos, lysosome enlargement was not observed at the early phase of embryogenesis (before comma) when cell proliferation and organogenesis occur, but was very obvious after the 2-fold stage, during which extensive morphogenesis occurs and cell proliferation almost ceases ([Figure 1---figure supplement 1Q](#fig1s1){ref-type="fig"}) ([@bib34]). It is possible that excessive ribosomes are removed at the late phase of embryogenesis to cope with the lower demand for protein synthesis and the high levels of energy that are required for morphogenesis and hatching. Although supplements of uridine or cytidine significantly reduced the embryonic lethality in *rnst-2;pyr-1* double mutants, it did not obviously improve the embryonic viability of *rnst-2(qx245)* single mutants, suggesting that the developmental phenotype may be attributed to defects in both general autophagy and nucleotide supply.

In addition to late embryonic and early larval stages, enlarged lysosomes are also present in *rnst-2* adults, and the *rnst-2* mutation reduces the lifespan of both wild-type and long-lived *daf-2* and *glp-1* worms. This suggests that lysosomal degradation of ribosomes also occurs during adulthood and may contribute to longevity. Lysosome-dependent ribosome turnover may help to clear defective ribosomes generated during aging and/or contribute to downregulation of protein translation. It is reported recently that NUFIP1 serves as a receptor for the selective autophagy of ribosomes in mammalian cells under nutrient starvation conditions to supply nucleosides required for cell survival during starvation ([@bib40]). Here we found that ribosome degradation through the autophagy-lysosome pathway occurs under normal growth conditions and is important for development and longevity. Whether ribosomes are recognized and removed through selective or bulk autophagy during development and aging requires future investigations.

Our study reveals the essential role of autophagy-dependent ribosome degradation in animal development, which may be conserved through evolution as both the autophagy machinery and T2 family endoribonucleases are highly similar from worms to humans. Loss-of-function mutations in human RNASET2 lead to familial cystic leukoencephalopathy, which is considered as a lysosome storage disease, but how lysosomal rRNA accumulation leads to neuronal disease is unclear ([@bib13]; [@bib12]). Our finding that loss of *rnst-2* affects nucleotide homeostasis and partially impairs autophagy may provide further insights into the disease pathogenesis.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\    Designation                  Source or reference                                                        Identifiers                                                                                 Additional\
  or resource                                                                                                                                                                                                                    information
  -------------------------- ---------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------
  Gene\                      *rnst-2*                                                                                                WBGene00019624                                                                              Other name:\
  (*C. elegans*)                                                                                                                                                                                                                 CELE_K10C9.3

                             *rpl-5*                                                                                                 WBGene00004416                                                                              Other name:\
                                                                                                                                                                                                                                 CELE_F54C9.5

                             *rpl-25.2*                                                                                              WBGene00004439                                                                              Other name:\
                                                                                                                                                                                                                                 CELE_F52B5.6

                             *rps-3*                                                                                                 WBGene00004472                                                                              Other name:\
                                                                                                                                                                                                                                 CELE_C23G10.3

                             *rps-0*                                                                                                 WBGene00004469                                                                              Other name:\
                                                                                                                                                                                                                                 CELE_B0393.1

  Gene (human)               *rnaset2*                    National Center for\                                                       Gene ID: 8635                                                                               
                                                          Biotechnology Information                                                                                                                                              

  Strain\                    N2                           CGC                                                                        RRID:[WB-STRAIN:N2\_(ancestral)](https://scicrunch.org/resolver/WB-STRAIN:N2_(ancestral))   wild type (Bristol)
  (*C. elegans*)                                                                                                                                                                                                                 

                             XW1624                       DOI: 10.1126/science.1220281                                                                                                                                           *laat-1(qx42)*

                             XW5331                       DOI: 10.1016/j.cell.2010.04.034                                                                                                                                        *lgg-1(bp500)*

                             OK286                        DOI: 10.1042/BJ20131085                                                    RRID:[WB-STRAIN:OK286](https://scicrunch.org/resolver/WB-STRAIN:OK286)                      *pyr-1(cu8)*

                             HZ1690                       DOI 10.1016/j.devcel.2011.06.024                                           RRID:[WB-STRAIN:HZ1690](https://scicrunch.org/resolver/WB-STRAIN:HZ1690)                    *epg-6(bp242)*

                             SP507                        DOI: 10.1042/BJ20131085                                                    RRID:[WB-STRAIN:SP507](https://scicrunch.org/resolver/WB-STRAIN:SP507)                      *umps-1(mn160)*

                             CF1041                       DOI: 10.1126/science.1139952                                                                                                                                           *daf-2(e1370)*

                             HZ1687                       DOI: 10.1083/jcb.201209098                                                 RRID:[WB-STRAIN:HZ1687](https://scicrunch.org/resolver/WB-STRAIN:HZ1687)                    *atg-9(bp564)*

                             VC893                        DOI: 10.1016/j.cell.2010.04.034                                            RRID:[WB-STRAIN:VC893](https://scicrunch.org/resolver/WB-STRAIN:VC893)                      *atg-18(gk378)*

                             XW10781                      this paper                                                                                                                                                             *rnst-2(qx245)*

                             XW15104                      this paper                                                                                                                                                             *rnst-2(bp555)*

                             HZ1683                       DOI 10.1016/j.devcel.2011.06.024                                           RRID:[WB-STRAIN:HZ1683](https://scicrunch.org/resolver/WB-STRAIN:HZ1683)                    *atg-2(bp576)*

                             CF1903                       CGC                                                                        RRID:[WB-STRAIN:CF1903](https://scicrunch.org/resolver/WB-STRAIN:CF1903)                    *glp-1(e2144)*

                             XW5097                       RRID:[WB-STRAIN:PD4482](https://scicrunch.org/resolver/WB-STRAIN:PD4482)                                                                                               *lmp-1(nr2045)*

                             XW7251                       DOI: 10.1126/science.1220281                                                                                                                                           *qxIs354*\
                                                                                                                                                                                                                                 (*P~ced-1~*LAAT-1::GFP)

                             XW5399                       DOI: 10.1126/science.1220281                                                                                                                                           *qxIs257*\
                                                                                                                                                                                                                                 (*P~ced-1~*NUC-1::CHERRY)

                             XW8056                       DOI: 10.1083/jcb.201602090                                                                                                                                             *qxIs430*\
                                                                                                                                                                                                                                 (*P~scav-3~*SCAV-3::GFP)

                             XW10197                      DOI: 10.1083/jcb.201602090                                                                                                                                             *qxIs468*\
                                                                                                                                                                                                                                 (*P~myo-3~*LAAT-1::GFP)

                             XW642                        DOI: 10.1091/mbc.10.12.4311                                                                                                                                            *bIs1*\
                                                                                                                                                                                                                                 (*P~vit-2~*VIT-2::GFP)

                             RT688                        DOI: 10.1126/science.1220281                                                                                                                                           *pwIs281*\
                                                                                                                                                                                                                                 (*P~pie-1~*CAV-1::GFP)

                             XW8293                       DOI: 10.15252/embr.201438618                                                                                                                                           *qxEx4098*\
                                                                                                                                                                                                                                 (*P~ced-1~*GFP:ATG-18)

                             XW12615                      this paper                                                                                                                                                             *qxIs544*\
                                                                                                                                                                                                                                 (*P~rnst-2~*RNST-2::CHERRY)

                             XW13567                      this paper                                                                                                                                                             *qxEx6614*\
                                                                                                                                                                                                                                 (*P~rnst-2~*RNST-2(H118A)::CHERRY)

                             XW8783                       this paper                                                                                                                                                             *qxEx4279*\
                                                                                                                                                                                                                                 (*P~myo-3~*LAAT-1::GFP)

                             XW17778                      this paper                                                                                                                                                             *qxEx8302*\
                                                                                                                                                                                                                                 (*P~rnst-2~*RNASET2-CHERRY)

  Antibody                   anti-RPL-5\                  this paper                                                                                                                                                             WB(1:300)
                             (rat polyclonal)                                                                                                                                                                                    

                             anti-RPL-25.2\               this paper                                                                                                                                                             WB(1:300)
                             (rat polyclonal)                                                                                                                                                                                    

                             anti-RPS-0\                  this paper                                                                                                                                                             WB(1:1000)
                             (rat polyclonal)                                                                                                                                                                                    

                             anti-RPS-3\                  this paper                                                                                                                                                             WB(1:1000)
                             (rat polyclonal)                                                                                                                                                                                    

                             anti-CPL-1\                  DOI: 10.1126/science.1220281                                                                                                                                           WB(1:500)
                             (rat polyclonal)                                                                                                                                                                                    

                             anti-LGG-1\                  DOI: 10.1016/j.cell.2010.04.034                                                                                                                                        WB(1:1000);\
                             (rat polyclonal)                                                                                                                                                                                    Immunostaining(1:1000)

                             anti-alpha-Tubulin\          Sigma-Aldrich (Missouri, USA)                                              Cat \#T5168;\                                                                               WB(1:10000)
                             \                                                                                                       RRID:[AB_477579](https://scicrunch.org/resolver/AB_477579)                                  
                             (mouse monoclonal)                                                                                                                                                                                  

                             anti-SQST-1\                 DOI: 10.1016/j.cell.2010.04.034                                                                                                                                        Immunostaining\
                             (rat polyclonal)                                                                                                                                                                                    (1:1000)

                             anti-PGL-3\                  DOI: 10.1016/j.cell.2010.04.034                                                                                                                                        Immunostaining\
                             (rat polyclonal)                                                                                                                                                                                    (1:1000)

                             anti-SEPA-1\                 DOI: 10.1016/j.cell.2010.04.034                                                                                                                                        Immunostaining\
                             (rabbit polyclonal)                                                                                                                                                                                 (1:1000)

                             anti-HSP-60\                 DOI: 10.1126/science.1220281                                                                                                                                           WB(1:1000)
                             (mouse polyclonal)                                                                                                                                                                                  

                             anti-HEL-1\                  DOI: 10.1126/science.1220281                                                                                                                                           WB(1:500)
                             (rabbit polyclonal)                                                                                                                                                                                 

                             anti-RME-1\                  DOI: 10.1126/science.1220281                                                                                                                                           WB(1:1000)
                             (mouse polyclonal)                                                                                                                                                                                  

  Plasmids for generating\   pPD49.26-*P~rnst-2~*RNST-\   this paper                                                                                                                                                             Cloning described in\
  transgenic strains         2::CHERRY                                                                                                                                                                                           \'Plasmid construction\'

                             pPD49.26*-P~rnst-2~*\        this paper                                                                                                                                                             Cloning described in\
                             RNASET2::CHERRY                                                                                                                                                                                     \'Plasmid construction\'

                             pPD49.26-*P~rnst-2~*\        this paper                                                                                                                                                             Cloning described in\
                             RNST-2(H118A)::CHERRY                                                                                                                                                                               \'Plasmid construction\'

                             pPD49.26-*P*~rnst-2~RNST-\   this paper                                                                                                                                                             Cloning described in\
                             2(cDNA)::CHERRY                                                                                                                                                                                     \'Plasmid construction\'

  Plasmids for protein\      pET-21b-*rpl-25.2*           this paper                                                                                                                                                             Cloning described in\
  expression                                                                                                                                                                                                                     \'Plasmid construction\'

                             pET-21b*-rpl-5*              this paper                                                                                                                                                             Cloning described in\
                                                                                                                                                                                                                                 \'Plasmid construction\'

                             pET-21b*-rps-0*              this paper                                                                                                                                                             Cloning described in\
                                                                                                                                                                                                                                 \'Plasmid construction\'

                             pET-21b*-rps-3*              this paper                                                                                                                                                             Cloning described in\
                                                                                                                                                                                                                                 \'Plasmid construction\'

  Commercial assay or kit    Lysosome Isolation Kit       Sigma-Aldrich (Missouri, USA)                                              Cat \#LYSISO1                                                                               

                             RNeasy Plus Universal\       QIAGEN (Hilden, Germany)                                                   Cat \#73404                                                                                 
                             Mini Kit                                                                                                                                                                                            

  Chemical compound, drug    Uridine                      Sigma-Aldrich (Missouri, USA)                                              Cat \#U3003                                                                                 

                             Cytidine                     Sigma-Aldrich\                                                             Cat \#C4654                                                                                 
                                                          (Missouri, USA)                                                                                                                                                        

                             DAPI                         Vector Laboratories\                                                       Cat \#H-1200;\                                                                              
                                                          (California, USA)                                                          RRID:[AB_2336790](https://scicrunch.org/resolver/AB_2336790)                                

                             LysoTracker red              Invitrogen\                                                                Cat \#L7528                                                                                 
                                                          (Oregon, USA)                                                                                                                                                          

  Software, algorithm        Velocity                     PerkinElmer\                                                                                                                                                           
                                                          (Massachusetts, USA)                                                                                                                                                   

                             Zen                          Carl Zeiss\                                                                RRID:[SCR_01367](https://scicrunch.org/resolver/SCR_01367)                                  
                                                          (Oberkochen, Germany)                                                                                                                                                  
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*C. elegans* strains {#s4-1}
--------------------

*C. elegans* strains were cultured and maintained at 20°C using standard protocols ([@bib3]). The N2 Bristol strain was used as the wild-type strain except in single nucleotide polymorphism (SNP) mapping, in which Hawaiian strain CB4856 was used. The strains used in this work are listed in the key resources table.

Isolation, mapping, and cloning of *rnst-2* {#s4-2}
-------------------------------------------

The *qx245* and *bp555* mutations were isolated from genetic screens for lysosome- and autophagy-defective mutants, respectively. The *qx245* mutation was mapped to the left side of LG V at the genetic map position −17 (Snp-pkP5076) by single nucleotide polymorphism (SNP) mapping. Transformation rescue experiments were performed and a fosmid clone in this region, *WRM0636aH01*, possessed rescue activity. Whole genome sequencing identified a point mutation in the coding sequence of *K10C9.3* within *WRM0636aH01*. Expression of the long PCR fragment covering the open reading frame of *K10C9.3* fully rescued the *qx245* defect. The sequence of the *K10C9.3* gene was determined in both *qx245* and *bp555* alleles and molecular lesions were identified. *qx245* contained a G-to-A transition that results in a substitution of Gly 119 by Glu, while *bp555* contained a C-to-T transition that generates a premature stop codon after Pro55. Both mutant alleles were backcrossed with N2 strain at least four times before further analyses.

Lysotracker staining {#s4-3}
--------------------

\~50 worms aged to day 3 of adulthood were soaked for 1.5 hr in 80 µl LysoTracker red solution (Invitrogen, Oregon, USA), which was diluted as 1:200 by M9. Worms were then transferred to NGM plates with fresh OP50 and recovered for 2 hr before examination. All steps were performed in the dark.

Quantification of lysosome number and volume {#s4-4}
--------------------------------------------

Fluorescence images of embryos, larvae, and adults expressing LAAT-1::GFP or NUC-1: CHERRY in 10--15 *z*-series (0.5 µm/section) were captured by spinning-disk microscopy. Serial optical sections were reconstituted to 3D view and the number and volume of lysosomes were measured by Velocity software (PerkinElmer, Massachusetts, USA). At least 10 worms were quantified in each strain at each stage.

Microscopy and imaging analysis {#s4-5}
-------------------------------

Differential interference contrast and ﬂuorescence images were captured by an inverted confocal microscope (LSM880; Carl Zeiss, Oberkochen, Germany) with 488, 405 and 561 lasers and images were processed and viewed using Zen software (Carl Zeiss, Oberkochen, Germany). All images were taken at 20°C.

Generation of antibodies {#s4-6}
------------------------

Full-length RPL-5, RPL-25.2, RPS-3 and RPS-0 ribosomal proteins tagged with six Histidine residues (RPL-5-His~6~, RPL-25.2-His~6~, RPS-3-His~6~, RPS-0-His~6~) were expressed in *E. coli*. The recombinant proteins were purified by Ni-NTA agarose beads and the eluted RPL-5-His~6~, RPS-3-His~6~ and RPS-0-His~6~ proteins were used to raise polyclonal antibodies in rat. For RPL-25.2-His~6~, a specific protein band was excised from the SDS-PAGE and used to generate polyclonal antibody in rat. The RPL-5 and RPS-0 polyclonal antibodies were further purified using RPL-5 or RPS-0 recombinant proteins. All polyclonal antibodies were generated in the Antibody Center at NIBS (National Institute of Biological Sciences, Beijing, China).

Western blot analysis and immunostaining {#s4-7}
----------------------------------------

Mix-staged embryos of *C. elegans* were collected from aged adults by bleaching. Embryonic and worm lysates (day three adults) were obtained and analyzed by western blot using anti-LGG-1 antibodies and anti-α-tubulin antibodies (Sigma-Aldrich, Missouri, USA).

For immunostaining, mix-staged embryos were fixed by ice-cold methanol and acetone on glass sheets treated by 1% poly-lysine. After blocking with 1% BSA and 10% fetal calf serum in phosphate buffered saline (PBS), the samples were incubated with anti-LGG-1(1:1000 dilution), anti-SQST-1 (1:1000 dilution), anti-SEPA-1 (1:1000 dilution) or anti-PGL-3 (1:1000 dilution) antibodies at 4°C overnight. The samples were washed three times in PBST (PBS + 0.2% Tween 20) and incubated with the secondary antibody (1:200 dilution) (Jackson ImmunoResearch, Pennsylvania, USA) for 80 min at room temperature in the dark. The samples were washed three times, then stained with DAPI (Vector Laboratories, California, USA) and visualized using a Zeiss LSM880 confocal microscope.

Lysosome purification and examination of RNA accumulation {#s4-8}
---------------------------------------------------------

Lysosomes were purified from adult worms by a Lysosome Isolation kit (LYSISO1; Sigma-Aldrich, Missouri, USA) as described previously with modifications ([@bib25]). In brief, synchronized larvae one worms were cultured at 20°C to day 3 of adulthood and collected. Worm pellets were suspended in the extraction buffer supplied in the Lysosome Isolation kit and ruptured by glass beads with the FastPrep−24 Instrument (MP Biomedicals, Ohio, USA). The worm lysate was centrifuged at 14,000 rpm to precipitate the crude lysosomes. The crude lysosomes were diluted in 19% Optiprep Density Gradient Medium Solution and further separated on a sucrose density gradient (from bottom to top: 27%, 19%, 16%, 8%).

After centrifugation, lysosome enrichment was determined by the amount of processed CPL-1 (lysosomal cathepsin) in different fractions that contained the same amount of total proteins (from bottom to top: B1-4). The purity of the lysosome fraction (B3) was examined by antibodies that detect different intracellular organelles.

The purified lysosome fractions from different strains were examined for accumulation of ribosomal proteins by western blot and ribosomal RNAs by RNA purification (73404; QIAGEN, Hilden, Germany). The purified RNAs were separated and examined by agarose gel electrophoresis. At least three independent experiments were performed in each strain and average data are shown in [Figure 3](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.

Examination of embryonic development, larval development and lifespan {#s4-9}
---------------------------------------------------------------------

To examine embryonic development, \~20 young adult worms (24 hr post L4) were placed on a NGM plate with OP50 for 2 hr. The worms were then removed and the eggs laid on the plate were followed. After 10 hr, newly hatched L1 worms were counted and transferred every hour until no new L1 worms hatched out. The percentage of eggs that hatched every hour was calculated to show the progress of embryonic development, and the total percentage of hatched L1 was quantified to determine level of embryonic lethality. More than 150 embryos were quantified in each strain. At least three independent experiments were performed in each strain and the average result from three experiments is shown in [Figure 5](#fig5){ref-type="fig"}, [Figure 6](#fig6){ref-type="fig"}, [Figure 6---figure supplements 1](#fig6s1){ref-type="fig"} and [2](#fig6s2){ref-type="fig"}. To analyze larval development, 100 L1 worms were collected. After 48 hr incubation, newly developed L4 worms were counted and transferred every hour until no live larvae were present on the plate. The total percentage of fully developed L4 was quantified to determine the level of larval arrest. At least three independent experiments were performed in each strain and the average result from three experiments is shown in [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"} and [Figure 6---figure supplement 1E](#fig6s1){ref-type="fig"}. Lifespan assays were performed at 20°C or 25°C \[*glp-1(e2144)* and the control strains\] as described previously ([@bib11]). About 150 L4 worms (day 0) were picked to NGM plates with fresh OP50, 15 worms per plate. The surviving worms were counted every 2 days and were transferred to new plates to avoid interference from the progeny. The worms that crawled off the plate, exploded, bagged, or became contaminated were discarded. At least three independent experiments were performed for each strain. The representative survival curve is shown in [Figure 5D and F](#fig5){ref-type="fig"}, [Figure 6---figure supplement 1F and H](#fig6s1){ref-type="fig"} and the mean lifespan from three experiments is shown in [Figure 5E and G](#fig5){ref-type="fig"}, [Figure 6---figure supplement 1G and I](#fig6s1){ref-type="fig"}.

Quantification of L1 survival under starvation treatment {#s4-10}
--------------------------------------------------------

Mix-staged embryos were collected and placed in M9 buffer, so that their growth could be synchronized to the larvae 1 (L1) stage. The L1 worms were transferred equally to 96-well plates, with about 200 larvae per well. The worms were transferred to NGM plates with fresh OP50 every 2 days and the surviving larvae were quantified. At least three independent experiments were performed for each strain. The representative survival curve is shown in [Figure 4U](#fig4){ref-type="fig"} (left panel) and the mean lifespan from three independent experiments is shown in [Figure 4U](#fig4){ref-type="fig"} (right panel).

RNAi {#s4-11}
----

The bacteria-feeding RNAi protocol was used as described before ([@bib16]). In *pyr-1* RNAi (D2085.1; 3117--4214 nt) and *umps-1* RNAi (T07C4.1; 274--1400 nt) experiments,\~30 L1 or L2 worms (P0) were placed on the RNAi plates. Embryos of the F1 generation were collected and quantified for survival throughout embryonic development.

Nucleotide supplementation {#s4-12}
--------------------------

Uridine and cytidine (Sigma-Aldrich, Missouri, USA) were dissolved in distilled water to a final concentration of 1M and this stock solution was stored at −20°C. The stock solution of uridine or cytidine was supplied to both NGM plates and OP50 culture spotted onto NGM plates as a 1:10 dilution. L4 larvae (P0) were placed on uridine- or cytidine-containing plates and cultured to the next generation (F1). The survival of the F2 embryos was quantified.

Statistical analysis {#s4-13}
--------------------

The standard deviation (SD) was used as y-axis error bars for bar charts plotted from the mean value of the data. Data derived from different genetic backgrounds were compared by Student's two-tailed unpaired t test, one-way analysis of variance (ANOVA) with Tukey's *post hoc* test or two-way ANOVA with the Bonferroni *post hoc* test. Data were considered statistically different when p\<0.05. p\<0.05 is indicated with single asterisks, p\<0.001 with double asterisks and p\<0.0001 with triple asterisks (0.001 in a two-way ANOVA analysis).

Plasmid construction {#s4-14}
--------------------

To construct *P~rnst-2~*RNST-2::CHERRY, *P~rnst-2~*RNST-2 was amplified from N2 genomic DNA using primers PDFZ482/PYBL29 and was ligated to pPD49.26-nCHERRY3 through the Nhe I/Nco I sites. To generate the *P~rnst-2~*RNASET2::CHERRY reporter, the 2.1 kb promoter of *rnst-2* was amplified from N2 genomic DNA using primers PYBL42/PYBL43 and cloned into pPD49.26-nCHERRY3 through the BamH I site. RNASET2 of *Homo sapiens* was amplified from a human cDNA library using the primers PDFZ487/PDFZ488 and cloned into *P~rnst-2~*nCHERRY3 through the Nhe I/Nco I sites. *P~rnst-2~*RNST-2(H118A)::CHERRY was generated through PCR-based site-directed mutagenesis using the primers PDFZ485/PDFZ486 on *P~rnst-2~*RNST-2(cDNA)::CHERRY. The cDNA of *rnst-2* was amplified from a *C. elegans* cDNA library (Invitrogen, Oregon, USA) using primers PYBL32/PYBL41 and cloned into *P~rnst-2~*nCHERRY3 through the Nhe I site. The RNST-2(H118A) fragment was digested from *P~rnst-2~*RNST-2(H118A)::CHERRY after mutagenesis, and re-ligated to *P~rnst-2~*nCHERRY3 through the Nhe I site. For the protein expression vectors, the cDNAs of *rpl-25.2*, *rps-3* and *rps-0* were amplified from a *C. elegans* cDNA library (Invitrogen, Oregon, USA) using primers PYBL64/PYBL65, PYBL70/PYBL71 and PYBL67/PYBL68, respectively, and ligated to pET21b vector through the Nde I/Xho I sites. The cDNA of *rpl-5* was amplified from a *C. elegans* cDNA library (Invitrogen, Oregon, USA) using the primers of PYBL99/PYBL101 and ligated to pET21b vector through the Nhe I/Xho I sites.

Primers used for plasmid construction {#s4-15}
-------------------------------------

PrimerSequence (5\' to 3\')PDFZ482\
PYBL29\
PYBL42\
PYBL43\
PDFZ487\
PDFZ488\
PDFZ485\
PDFZ486\
PYBL32\
PYBL41\
PYBL64\
PYBL65\
PYBL70\
PYBL71\
PYBL67\
PYBL68\
PYBL99\
PYBL101GCCCATGGCATTTCCAATATTTTTGATAGCGCTCC\
GCGCTAGCCCGTGGGAGTAATGTTGC\
GCGGATCCTTCTGGAAATCTTGCGTGAT\
GCGGATCCGGCGACTACTGTAAACGA\
CGGCTAGCATGCGCCCTGCAGCCCTGCGCGG\
GCCCATGGCATGCTTGGTCTTTTTAGGTGGGG\
GAAACACGAGTATGATAAGGCCGGGACATGTGCTCAAAG\
CTTTGAGCACATGTCCCGGCCTTATCATACTCGTGTTTC\
GCGCTAGCATGAAACTTCTCCTTCTTCTCT\
GCGCTAGCATTTCCAATATTTTTGATAGCG\
GCCATATGATGGCTCCGTCATCAAACAAAG\
GCCTCGAGGATGAATCCGATCTTGTTGGCA\
GCCATATGATGGCTGCCAATCAAAACGTGA\
GCCTCGAGTTGAACTGGAGCAACTGGTTGA\
GCCATATGATGTCAGGCGGTGCCGCTCATT\
GCCTCGAGCCAGTTAGACTGGGTTGGAGCG\
GCGCTAGCATGGGTCTCGTCAAGGTCATTA\
GCCTCGAGCTCCTGTTGCTCCTTGAGTT
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The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This study reports that *C. elegans* RNST-2, a lysosomal T2 family endoribonuclease, is required for autophagic degradation of ribosomal RNAs and is critical for development and survival of *C. elegans* embryos and larvae. Importantly, the authors find that simultaneous suppression of RNST-2 and de novo synthesis of pyrimidine nucleotides causes complete lethality and that this phenotype can be rescued by uridine/cytidine supplementation. These results suggest that RNST-2-dependent lysosomal RNA turnover is critical for a pyrimidine nucleotide recycling, general lysosomal function, and worm development. This work potentially represents a significant advancement in the field. However, there are several points that should be clarified.

Essential revisions:

(Comments 1, 2, and 3 are related)

1\) One of the main conclusions is that lysosomal turnover of RNAs is important for providing nucleotides. Although this can be hypothesized by the data, the levels of nucleotides are not directly measured in mutants. Quantification of nucleotides in wild-type and *rnst-2, pyr-1, pyr-1;rnst-2*, and some *atg* mutants would directly support this conclusion.

2\) In Figure 4F and G, although uridine or cytidine supplementation rescues embryonic lethality of *rnst-2* mutants, it does not improve embryonic viability of *rnst-2* mutants. It could indicate that reduced embryonic lethality is not caused primarily by defects in the supply of pyrimidines. Instead, other functions of RNST-2 could be the cause of embryonic lethality of *rnst-2* mutants. For example, a general defect in autophagy could be the reason behind both embryonic lethality and synthetic lethality phenotypes. This point should be clarified to prove the recycling hypothesis.

3\) As autophagy mutants such as *lgg-1(bp500), atg-18(gk378), atg-2(bp576)* also show partial embryonic lethality, it is still unclear whether this lethality is caused by a defect in RNA degradation or other molecules. The embryonic lethal phenotype of autophagy mutants should also be tested with uridine or cytidine supplementation.

4\) Another important conclusion is that general lysosomal function is impaired in *rnst-2* mutants. If this is due to accumulation of autophagy-derived RNAs, is not only the size of lysosomes (Figure 3E) but also their function (e.g. degradation of endocytosed cargos) restored by additional deletion of autophagy genes such as *atg-2*?

5\) The data presented here also suggest that the autophagy pathway itself is affected in *rnst-2* mutants. In Figure 4---figure supplement 1, the accumulation of LGG-1-I is difficult to explain simply by lysosomal dysfunction. Generally, impairment of lysosomal function causes accumulation of LGG-1/ATG8-II, but not -I. The result rather suggests that autophagy induction or autophagosome formation may also be affected. To further characterize the autophagy pathway, additional assays (i.e. measurement of autophagic flux using bafilomycin A1 and testing accumulation of phagophore markers such as ATG1 and ATG18). This is important because in other organisms (e.g., *Arabidopsis*) autophagosomes accumulate in *rnst-2* mutants in an attempt to compensate for inhibition of RNA degradation.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Autophagy-dependent rRNA degradation is essential for maintaining nucleotide homeostasis during *C. elegans* development\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Ivan Dikic (Senior Editor), a Reviewing Editor, and two reviewers.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

We appreciate that you have made a substantial effort to address the comments and criticisms of the first review round. We have assessed this revised version in consultation with the two original reviewers.

1\) We also think that the new results shown in [Author response image 1](#respfig1){ref-type="fig"} is indeed paradoxical; the level of uridine in *rnst-2;pyr-1* mutant embryos is higher than in control embryos. This is contradictory to the main result that uridine supplementation can suppress the lethality of the double mutants. However, we understand that it may be difficult to accurately measure the nucleotide levels using heterogeneous tissues in unhealthy embryos (with the intact purine synthesis pathway) and the results may not reflect the situation in key organs causing the phenotype. We agree that the other data support your recycling hypothesis. Given this situation, it would be fair to state that you have tried to measure the nucleoside levels and observed a reduction in cytidine but not in guanosine (even without showing the data) and discuss potential limitations or difficulties of this experiment.

2\) Although it would be difficult to clearly separate phenotypes caused by a defect in general autophagy from those by a defect in nucleoside supply, this point should be more clearly discussed in the Discussion section. The phenotype should be caused by both defects.

3\) During the revision, a related paper on autophagy-mediated nucleotide recycling was published by David Sabatini\'s group (Wyant et al., 2018). You may want to cite this paper and discuss a relationship with this paper.

10.7554/eLife.36588.030

Author response

> Essential revisions:
>
> (Comments 1, 2, and 3 are related)
>
> 1\) One of the main conclusions is that lysosomal turnover of RNAs is important for providing nucleotides. Although this can be hypothesized by the data, the levels of nucleotides are not directly measured in mutants. Quantification of nucleotides in wild-type and rnst-2, pyr-1, pyr-1;rnst-2, and some atg mutants would directly support this conclusion.

As suggested by the reviewer, we measured the levels of 4 nucleosides (adenosine, guanosine, cytidine and uridine) and UMP by LC/MS (Agilent 1290 HPLC coupled to an Agilent 6495 Triple Quadrupole mass spectrometer). We first measured the nucleoside levels in samples prepared from mix-staged worms, but they gave very big variations, likely due to asynchronization of the worms. We then switched to measurements using mix-staged embryos, which are hard to collect but showed less variations than the mix-staged worm samples. We utilized RNAi treatment in these experiments because (1) *pyr-1;rnst-2* double mutants do not produce viable progeny and we were unable to collect enough embryos for measurements; (2) *rnst-2;pyr-1(RNAi)* exhibited synthetic embryonic lethality as in double mutants, but the RNAi treatment can be achieved on a sufficiently large scale to obtain enough embryos for LC-MS analyses. We found that levels of adenosine, guanosine, cytidine, uridine and UMP were all obviously decreased in *rnst-2(qx245)* and *pyr-1(RNAi)* embryos compared to wild type, consistent with the role of RNST-2 and PYR-1 in maintaining nucleotide homeostasis ([Author response image 1](#respfig1){ref-type="fig"}). In *rnst-2;pyr-1(RNAi)*, the cytidine level appeared to be further reduced, while levels of adenosine and UMP were similar to those in single mutants ([Author response image 1A, C, E](#respfig1){ref-type="fig"}). Unexpectedly, however, levels of guanosine and uridine were higher in *rnst-2;pyr-1(RNAi)* than in wild type and single mutants ([Author response image 1B, D](#respfig1){ref-type="fig"}). We do not understand why guanosine and uridine levels increased in *rnst-2;pyr-1(RNAi)*. Since RNA inactivation reduces but does not completely disrupt PYR-1 function, it is possible that feed-back responses may be elicited in *rnst-2;pyr-1(RNAi)*, which lead to increased guanosine and uridine through de novo or salvage pathways. However, this is pure speculation and we do not have a straight forward approach to test this hypothesis due to the high complexity and our incomplete understanding of the pyrimidine and purine metabolism pathways in worms. We therefore did not include these data in the revised manuscript. Nevertheless, except for the increase in guanosine and uridine levels in *rnst-2;pyr-1(RNAi)* embryos, the nucleoside measurement results are all consistent with the genetic and cell biology data and support the idea that lysosomal turnover of RNA is important for providing nucleotides.

![Quantitative analysis of nucleosides.\
Mix-staged embryos were collected and ground. The metabolites were extracted, and nucleosides and UMP were analyzed by LC/MS. The level of each nucleoside is presented as the absolute concentration, and the UMP level is presented as normalized intensity on the basis of the total peak area.](elife-36588-resp-fig1){#respfig1}

> 2\) In Figure 4F and G, although uridine or cytidine supplementation rescues embryonic lethality of rnst-2 mutants, it does not improve embryonic viability of rnst-2 mutants. It could indicate that reduced embryonic lethality is not caused primarily by defects in the supply of pyrimidines. Instead, other functions of RNST-2 could be the cause of embryonic lethality of rnst-2 mutants. For example, a general defect in autophagy could be the reason behind both embryonic lethality and synthetic lethality phenotypes. This point should be clarified to prove the recycling hypothesis.
>
> 3\) As autophagy mutants such as lgg-1(bp500), atg-18(gk378), atg-2(bp576) also show partial embryonic lethality, it is still unclear whether this lethality is caused by a defect in RNA degradation or other molecules. The embryonic lethal phenotype of autophagy mutants should also be tested with uridine or cytidine supplementation.

As suggested by the reviewer, we examined embryonic lethality in *lgg-1, atg-18* and *atg-2* without and with uridine or cytidine supplements. Like in *rnst-2* single mutants, uridine and cytidine supplements did not rescue the partial embryonic lethality in these autophagy-defective mutants, although cytidine supplement increased the viability of *atg-18* embryos (Figure 6---figure supplement 2C, D). These data and our finding that loss of *rnst-2* partially impairs autophagy together suggest that a general autophagy defect may contribute to the partial embryonic lethality in *rnst-2* and autophagy-defective mutants.

We found that in *pyr-1* and *umps-1* mutants, which have a blockage in de novo synthesis of pyrimidines, loss of RNST-2, but not LAAT-1 (lysosomal amino acid transporter) or LMP-1/LAMP1, leads to complete embryonic lethality. This indicates that loss of RNST-2 function, but not a general defect of lysosomes, leads to the synthetic embryonic lethality (Figure 6A, B and Figure 6---figure supplement 1C-E). Although supplements of uridine or cytidine did not obviously improve the viability of *rnst-2* single mutants, these treatments efficiently suppressed the synthetic lethality in *pyr-1;rnst-2* double mutants (Figure 6C, E). This strongly suggests that the synthetic lethality is mainly caused by defective supply of nucleotides.

We have included the new rescue data in the revised manuscript to indicate that a general autophagy defect contributes to the embryonic lethality in *rnst-2* and autophagy-defective mutants.

> 4\) Another important conclusion is that general lysosomal function is impaired in rnst-2 mutants. If this is due to accumulation of autophagy-derived RNAs, is not only the size of lysosomes (Figure 3E) but also their function (e.g. degradation of endocytosed cargos) restored by additional deletion of autophagy genes such as atg-2?

In *rnst-2*, we examineddegradation of the endocytic cargos CAV-1 and VIT-2, and of apoptotic cells, which are engulfed and degraded in lysosomes through the phagocytic pathway. We found that CAV-1, VIT-2 and apoptotic cell corpses are properly degraded in *rnst-2* as in wild type (Figure 3---figure supplement 2). Thus, loss of RNST-2 affects degradation of autophagic but not endocytic or phagocytic cargos.

> 5\) The data presented here also suggest that the autophagy pathway itself is affected in rnst-2 mutants. In Figure 4---figure supplement 1, the accumulation of LGG-1-I is difficult to explain simply by lysosomal dysfunction. Generally, impairment of lysosomal function causes accumulation of LGG-1/ATG8-II, but not -I. The result rather suggests that autophagy induction or autophagosome formation may also be affected. To further characterize the autophagy pathway, additional assays (i.e. measurement of autophagic flux using bafilomycin A1 and testing accumulation of phagophore markers such as ATG1 and ATG18). This is important because in other organisms (e.g., Arabidopsis) autophagosomes accumulate in rnst-2 mutants in an attempt to compensate for inhibition of RNA degradation.

As suggested by the reviewer, we performed additional experiments to further characterize the autophagy process in *rnst-2* mutants. Unfortunately, we do not have an efficient way to completely block lysosome function in *C. elegans* (bafilomycin A1 treatment did not work well), and therefore we are unable to measure autophagic flux precisely in *rnst-2* mutants. To further examine the autophagy process in *rnst-2*, we did the following experiments:

1\) We examined accumulation of PGL granules, which are efficiently removed by selective autophagy during embryogenesis. This process is very sensitive to changes in autophagy activity (Zhang et al., 2009; Tian et al., 2010). The PGL granule component PGL-3 and the bridging molecule SEPA-1 failed to be removed and thus persisted in *atg-2* mutants (Figure 4---figure supplement 1). However, PGL-3 and SEPA-1 were removed in *rnst-2* mutants as in wild type, indicating that autophagic clearance of PGL granules is normal (Figure 4---figure supplement 1).

2\) SQST-1/p62 associates with various protein aggregates that are removed by autophagy, while LGG-1/ATG8 associates with autophagic structures from early to late stages. Both SQST-1 and LGG-1 are substrates of autophagy. We found that SQST-1 and LGG-1 puncta were removed in wild type but were present in late-staged embryos in *rnst-2* mutants (Figure 4 and Figure 4---figure supplement 1). In *atg-2* mutants, however, SQST-1 and LGG-1 puncta persisted in embryos at both early and late stages (Figure 4). These data suggest that the autophagy process is partially impaired or delayed in *rnst-2(lf)*, causing accumulation of SQST-1 and LGG-1 in late-staged embryos.

3\) *rnst-2* mutants accumulated both LGG-1-I and LGG-1-II (lipid-conjugated form of LGG-1) at both embryonic and adult stages, consistent with partial impairment of autophagy (Figure 4).

4\) We found that GFP::ATG-18, which associates with early autophagic structures, was diffuse in the cytoplasm in both wild type and *rnst-2* mutant embryos, suggesting that autophagosome formation is not blocked (Figure 4---figure supplement 2).

5\) Loss of *rnst-2* leads to shortened lifespan of L1 larvae in the absence of food, a process that requires autophagy activity.

Altogether, these data suggest that the autophagy process is partially impaired in *rnst-2* mutants. We suspect that the gradual buildup of undigested rRNA and ribosomal proteins in *rnst-2* lysosomes leads to impaired autophagy kinetics and thus causes a reduction in autophagic flux. This is in fact consistent with the notion that dysregulation of autophagy serves as a common mechanism underlying lysosomal storage diseases that are characterized by the accumulation of undegraded metabolites in lysosomes.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> We appreciate that you have made a substantial effort to address the comments and criticisms of the first review round. We have assessed this revised version with consultation with the two original reviewers.
>
> 1\) We also think that the new results shown in [Author response image 1](#respfig1){ref-type="fig"} in the rebuttal letter is indeed paradoxical; the level of uridine in rnst-2;pyr-1 mutant embryos is higher than in control embryos. This is contradictory to the main result that uridine supplementation can suppress the lethality of the double mutants. However, we understand that it may be difficult to accurately measure the nucleotide levels using heterogeneous tissues in unhealthy embryos (with the intact purine synthesis pathway) and the results may not reflect the situation in key organs causing the phenotype. We agree that the other data support your recycling hypothesis. Given this situation, it would be fair to state that you have tried to measure the nucleoside levels and observed a reduction in cytidine but not in guanosine (even without showing the data) and discuss potential limitations or difficulties of this experiment.

We have included the statement regarding nucleoside measurement in the Discussion section as suggested, and discussed the limitation of the experiments.

> 2\) Although it would be difficult to clearly separate phenotypes caused by a defect in general autophagy from those by a defect in nucleoside supply, this point should be more clearly discussed in the Discussion section. The phenotype should be caused by both defects.

We have revised the Discussion section as suggested to indicate clearly that the development phenotype may be caused by defects in both general autophagy and nucleotide supply.

> 3\) During the revision, a related paper on autophagy-mediated nucleotide recycling was published by David Sabatini\'s group (Wyant et al., 2018). You may want to cite this paper and discuss a relationship with this paper.

We have cited the paper published by David Sabatini's group and discussed the potential relationship with our study (subsection "Ribosomal RNA degradation through the autophagy-lysosome pathway is important in maintaining nucleotide homeostasis essential for animal development").
